SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors
Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer
Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma
Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors